Provider: Ingenta Connect Database: Ingenta Connect Content: application/x-research-info-systems TY - ABST AU - Urueña, Analía AU - González, Jorge E. AU - Rearte, Analía AU - Pérez Carrega, María E. AU - Calli, Rogelio AU - Pagani, María F. AU - Uboldi, Andrea AU - Vicentín, Rosalía AU - Caglio, Patricia AU - Cañero-Velasco, María C. AU - Gentile, Angela AU - Ramonet, Margarita AU - Vizzotti, Carla TI - Single-dose Universal Hepatitis A Immunization in One-year-old Children in Argentina JO - The Pediatric Infectious Disease Journal PY - 2016-12-01T00:00:00/// VL - 35 IS - 12 SP - 1339 EP - 1342 KW - children KW - immunogenicity KW - long-term follow-up KW - Argentina KW - hepatitis A KW - single-dose vaccination N2 - Background:

Single-dose hepatitis A virus (HAV) vaccination was implemented in all Argentinean children 12 months of age in 2005. Previous studies demonstrated high prevalence of protective antibody response 4 years after single-dose vaccination. This study assessed long-term seroprotection against HAV after vaccination.

Methods:

Children who received 1 dose of HAV vaccine at 1 year of age at least 6 years before enrollment were included at 5 centers in Argentina between 2013 and 2014. Demographic and socioeconomic characteristics were collected through a questionnaire. Blood samples were tested for anti-HAV antibodies. Antibody values ≥10 mIU/mL were considered seroprotective. Logistic regression analysis was performed to evaluate the association between demographic and socioeconomic variables and seroprotection.

Results:

A total of 1088 children were included, with a median postvaccination interval of 7.7 years (range 6.3–9.2 years). Of these children, 97.4% (95% confidence interval: 96.3%–98.3%) had protective antibodies against HAV. No association between demographic or socioeconomic variables and seroprotection was found. Geometric mean concentration of antibody levels against HAV was 170.5 mUI/mL (95% confidence interval: 163.2–178.2 mUI/mL).

Conclusions:

Single-dose universal hepatitis A immunization in 1-year-old children resulted in sustained immunologic protection for up to 9 years in Argentina. These findings, along with the low current disease burden, confirm the success of the intervention. UR - https://www.ingentaconnect.com/content/wk/inf/2016/00000035/00000012/art00020 M3 - doi:10.1097/INF.0000000000001322 UR - https://doi.org/10.1097/INF.0000000000001322 ER -